Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower plasma glucose concentration by inhibiting Na -glucose-coupled transport in the proximal tubule. Clinical trials demonstrate these drugs have favorable effects on cardiovascular outcomes to include slowing the progression...

Full description

Bibliographic Details

Published in:	Clinical journal of the American Society of Nephrology Vol. 16; no. 8; p. 1284
Main Authors:	Palmer, Biff F, Clegg, Deborah J
Format:	Journal Article
Language:	English
Published:	United States 01.08.2021
Subjects:	Blood Glucose - metabolism Humans Ketosis - blood Ketosis - chemically induced Ketosis - physiopathology Ketosis - therapy Kidney - drug effects Kidney - physiopathology Risk Factors Sodium-Glucose Transporter 2 Inhibitors - adverse effects euglycemic ketoacidosis sodium glucose co-transporter inhibitor
ISSN:	1555-905X, 1555-905X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!